<DOC>
	<DOC>NCT00525902</DOC>
	<brief_summary>The purpose of this study is to assess the safety and efficacy of Adalimumab in uveitis.</brief_summary>
	<brief_title>Adalimumab (Humira) in the Treatment of Refractory Non-infectious Uveitis</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1. Patients with visionthreatening autoimmune uveitis. 2. Failure to respond to prednisone and at least one other systemic immunosuppressive (such as methotrexate, azathioprine, mycophenolate mofetil, cyclosporine, cyclophosphamide, or chlorambucil), or intolerance to such medications due to side effects. 1. Serious concomitant illness that could interfere with the subject's participation in the trial. 2. Previous or current use of cyclophosphamide. 3. Unable or unwilling to undergo multiple injections.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>